Keyword: Elusys Therapeutics

anthrax

3. Anthim

After receiving years of federal support to the tune of more than $240 million, Elusys won approval in May for its Anthim to treat inhalational anthrax, caused by exposure to contaminated animals or by an intentional release of bacteria spores.